At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points in the proliferation marker, Ki67, for clinical decision making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement